ATR and neoplasm: In breast cancers with overexpression of low‐molecular‐weight cyclin E, ATR inhibition reduces cell viability by targeting the ATR–CHK1–RAD51 axis, underscoring the increased reliance of replication‐stress‐tolerant tumours on this pathway.96